HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Chemoprevention of colon cancer by organoselenium compounds and impact of high- or low-fat diets.

AbstractBACKGROUND:
Observational and experimental studies have suggested that dietary supplementation with selenium can inhibit the development of colon cancer. However, many forms of selenium are toxic. Consequently, the development of efficacious compounds with low toxicity has been pursued.
PURPOSE:
Two synthetic organoselenium compounds, p-methoxy-benzyl selenocyanate (p-methoxy-BSC) and 1,4-phenylenebis(methylene)selenocyanate (p-XSC), were tested for their ability to inhibit colon carcinogenesis in rats that were treated with the carcinogen azoxymethane and fed low- or high-fat diets.
METHODS:
Groups of 5-week-old male F344 rats (42 animals/ group) were fed either a high-fat diet or a low-fat diet with or without added p-methoxy-BSC (10 or 20 parts per million [ppm]) or p-XSC (20 ppm). Two weeks later, 30 animals in each group received a subcutaneous injection of azoxymethane (15 mg/kg body weight); 1 week later, they received a second injection. The remaining 12 rats in each group received two injections of saline. Three days after the second injection of carcinogen or saline, animals being fed diets with p-methoxy-BSC or p-XSC were switched to corresponding organoselenium-free low- or high-fat diets for the remainder of the study to determine the effects of the selenium compounds on the initiation phase of colon carcinogenesis. At that time, groups of animals that had been maintained on organoselenium-free low- or high-fat diets were switched to diets containing p-methoxy-BSC or p-XSC until the end of the study to determine the effects of these compounds on the postinitiation phase of colon carcinogenesis. All animals were killed during the 38th week after azoxymethane or saline treatment, and histopathologic analysis of the colon tumors was performed. Colon tumor incidence and multiplicity were analyzed statistically.
RESULTS:
No obvious toxic effects were observed following dietary administration of 10 or 20 ppmp-methoxy-BSC or 20 ppm p-XSC. Administration of 20 ppm p-methoxy-BSC in a high-fat diet during the initiation and postinitiation phases of colon carcinogenesis significantly (statistically) reduced colon tumor incidence; 10 ppmp-methoxy-BSC in a high-fat diet significantly reduced colon tumor incidence but only when it was given during the postinitiation phase. Colon tumor incidence was also significantly reduced when 20 ppm p-XSC was given in a high-fat diet during the initiation phase of colon carcinogenesis. When 20 ppm p-XSC was administered in either a high-fat diet or a low-fat diet during the postinitiation phase, both colon tumor incidence and multiplicity were significantly reduced; the greatest reductions were in animals fed a low-fat diet.
CONCLUSIONS:
In this model system, p-methoxy-BSC and p-XSC are effective agents for the chemoprevention of colon cancer. The effects of p-XSC were enhanced in animals fed a low-fat diet.
AuthorsB S Reddy, A Rivenson, K El-Bayoumy, P Upadhyaya, B Pittman, C V Rao
JournalJournal of the National Cancer Institute (J Natl Cancer Inst) Vol. 89 Issue 7 Pg. 506-12 (Apr 02 1997) ISSN: 0027-8874 [Print] United States
PMID9086007 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Anticarcinogenic Agents
  • Cyanates
  • Dietary Fats
  • Organoselenium Compounds
  • benzyl selenocyanate
  • 1,4-phenylenebis(methylene)selenocyanate
  • Azoxymethane
Topics
  • Adenocarcinoma (chemically induced, pathology, prevention & control)
  • Analysis of Variance
  • Animals
  • Anticarcinogenic Agents (therapeutic use)
  • Azoxymethane
  • Colonic Neoplasms (chemically induced, pathology, prevention & control)
  • Cyanates (therapeutic use)
  • Dietary Fats (administration & dosage)
  • Dose-Response Relationship, Drug
  • Incidence
  • Logistic Models
  • Male
  • Neoplasm Invasiveness
  • Organoselenium Compounds (therapeutic use)
  • Rats
  • Rats, Inbred F344

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: